With the introduction of Damonzia®, Cobel Darou has taken a significant step forward in advancing oral therapies for chronic autoimmune diseases. By focusing on faster disease control and achieving more sustained efficacy, this next-generation treatment establishes a new paradigm in the long-term management of autoimmune conditions.

Its oral administration, convenience of use, and the elimination of frequent injections make this medication a distinct and advantageous alternative to many biologic therapies in controlling symptoms and enhancing the patient experience. With its rapid onset of action and sustained efficacy, Damonzia® significantly improves symptoms from the very first weeks of treatment.

Damonzia® (generic name: Upadacitinib) represents a new generation of oral therapies introduced to manage a broad spectrum of chronic autoimmune and inflammatory diseases. These include Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Atopic Dermatitis, and Inflammatory Bowel Diseases (IBD) such as Ulcerative Colitis and Crohn’s Disease. By providing an effective oral solution, this medication helps patients achieve long-term therapeutic stability alongside rapid disease control, dramatically improving their quality of life.

Inflammatory autoimmune diseases encompass a group of conditions wherein the body’s immune system mistakenly attacks healthy cells for unknown reasons, causing damage and inflammation in various parts of the body, such as the joints, skin, and gastrointestinal tract. The primary goal in treating autoimmune diseases is the sustained control of symptoms and the enhancement of the patient’s quality of life.

Through the selective and targeted inhibition of key inflammatory pathways, Damonzia® helps reduce inflammation and disease symptoms, empowering patients to lead more active and higher-quality lives.

Damonzia® is produced by Cobel Darou in collaboration with Dr. Abidi Pharmaceuticals and is approved by the Iran Food and Drug Administration (IFDA). This medication is available strictly by prescription (Rx-only) and is accessible to patients at pharmacies nationwide.

About Cobel Darou

For over 20 years, Cobel Darou has been actively engaged in the manufacturing, importation, and distribution of under-license pharmaceutical products in collaboration with international pharmaceutical companies. By supplying essential medications for Iranian patients—particularly specialty medications—the company plays a pivotal role in elevating public health standards and improving individual quality of life.

IR-0328-DMN-5127-PR